Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Galapagos ( (GLPG) ) has shared an announcement.
On January 7, 2025, Galapagos NV announced it has entered into a Separation Agreement with Gilead Sciences, Inc. and Gilead Therapeutics A1 Unlimited Company. The agreement entails transferring certain cash balances, assets, and liabilities to a new entity, SpinCo. This strategic move aims to separate Galapagos into two public companies, allowing shareholders to receive equivalent shares in the new entity, SpinCo. The transaction is subject to Belgian law and shareholder approval at an Extraordinary Shareholders’ Meeting. This separation could potentially impact Galapagos’ operations, providing an opportunity for the two companies to succeed independently in their respective markets.
More about Galapagos
Galapagos NV is a Belgian clinical-stage biotechnology company listed on the Euronext Brussels, Amsterdam, and NASDAQ Stock Markets. It specializes in the discovery and development of innovative medicines for the treatment of autoimmune diseases and cancer.
YTD Price Performance: -16.52%
Average Trading Volume: 267,518
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.5B
For an in-depth examination of GLPG stock, go to TipRanks’ Stock Analysis page.
